EPHB6 and prostate cancer: EPHB6 lacks catalytic activity due to several intrinsic alterations in the sequence of its kinase domain [4] and in contrast to other Eph receptors [5–7], EPHB6 is often downregulated in various malignancies, including metastatic lung cancer [8], melanoma [9], prostate cancer [10], ovarian carcinoma [11], gastric cancer [12], aggressive neuroblastoma [13, 14], and invasive breast cancer cell lines [15, 16].